Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity

20 Jun 2019

Abstract excerpt

Cervical cancer caused by infection with Human papillomaviruses (HPVs) is the 4th most common cancer in women globally, with the burden mainly in developing countries due to limited healthcare resources. Current vaccines based on virus-like particles (VLPs) assembled from recombinant expression of the immunodominant L1 protein are highly effective in the prevention of cervical infection; however, these vaccines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Immunotherapy and Immune Responses
Share to Transgenic Plants and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31281327
DOI: 10.3389/fpls.2019.00779

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and ImmunogenicityPMID 31281327Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Semantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2Semantic proximity Read ↗

In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccineSemantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificitySemantic proximity Read ↗

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read ↗

Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.Semantic proximity Read ↗

Modification of human papillomavirus‐like particle vaccine by insertion of the cross‐reactive L2‐epitopesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.